MedChemExpress - Model Zaltoprofen -74711-43-6
Zaltoprofen (CN100), a non-steroidal anti-inflammatory drug (NSAID), is a preferential and orally active COX-2 inhibitor, with IC50s of 1.3 and 0.34 μM for COX-1 and COX-2, respectively. Zaltoprofen exhibits powerful anti-inflammatory effects as well as an analgesic action on inflammatory pain[1][2][3].MCE products for research use only. We do not sell to patients.
Zaltoprofen
MCE China：Zaltoprofen
Brand：MedChemExpress (MCE)
Cat. No.HY-B0619
CAS：74711-43-6
Synonyms：CN100
Purity：99.28%
Storage：Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Shipping：Room temperature in continental US; may vary elsewhere.
Description：Zaltoprofen (CN100), a non-steroidal anti-inflammatory drug (NSAID), is a preferential and orally active COX-2 inhibitor, with IC50s of 1.3 and 0.34 μM for COX-1 and COX-2, respectively. Zaltoprofen exhibits powerful anti-inflammatory effects as well as an analgesic action on inflammatory pain.
In Vitro：Zaltoprofen (0.1-10 μM; 15 min) inhibits thromboxane B2 production in human platelets in a dose-dependent manner[1]. Zaltoprofen (0.01-1 μM; 30 min) inhibits prostaglandin E2 production by interleukin-1β-stimulated synovial cells[1]. Zaltoprofen (0.1-1 μM; 5 min) inhibits the bradykinin-induced increase of [Ca2+]i in DRG cells[2].
In Vivo：Zaltoprofen (5-20 mg/kg; a single p.o.) inhibits bradykinin-induced nociceptive responses in rats[2]. Zaltoprofen (3-30 mg/kg; a single p.o.) inhibits the acetic acid-induced writhing response of mice in a dose-dependent manner[2].
IC50 & Target：COX-2 0.34 μM (IC50) COX-1 1.3 μM (IC50)
Hot selling product：Arachidonic acid | Quercetin | Adalimumab | Adavosertib | ACY-738 | Etoposide | HP-β-CD | XMU-MP-1 | Estradiol | AEBSF (hydrochloride)
Trending products：Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Fluorescent Dye | PROTAC | Isotope-Labeled Compounds | Oligonucleotides
References：
[1]. Kawai S, et, al. Comparison of cyclooxygenase-1 and -2 inhibitory activities of various nonsteroidal anti-inflammatory drugs using human platelets and synovial cells. Eur J Pharmacol. 1998 Apr 17;347(1):87-94. [Content Brief]
[2]. Hirate K, et, al. Zaltoprofen, a non-steroidal anti-inflammatory drug, inhibits bradykinin-induced pain responses without blocking bradykinin receptors. Neurosci Res. 2006 Apr;54(4):288-94. [Content Brief]
[3]. Kameyama T, et, al. Analgesic and antiinflammatory effects of 2-(10,11-dihydro-10-oxo-dibenzo[b,f]thiepin-2-yl)propionic acid in rat and mouse. Arzneimittelforschung. 1987 Jan;37(1):19-26. [Content Brief]
Brand introduction:
• MCE (MedChemExpress) has a global exclusive compound library of more than 200 kinds, and we are committed to providing the most comprehensive range of high-quality small molecule active compounds for scientific research customers around the world；
• More than 50,000 highly selective inhibitors and agonists are involved in various popular signaling pathways and disease areas；
• The products cover a variety of recombinant proteins, peptides, commonly used kits, more PROTAC, ADC and other characteristic products, widely used in new drug research and development, life science and other scientific research projects；
• Provide virtual screening, ion channel screening, metabolomics analysis detection analysis, drug screening and other professional technical services；
• It has a professional experimental center and strict quality control and verification system；
• Provide LC/MS, NMR, HPLC, chiral analysis, elemental analysis and other quality inspection reports to ensure the high purity and high quality of products；
• The biological activity of the products has been verified by the experiments of customers in various countries；
• A variety of top journals such as Nature, Cell, Science and pharmaceutical patents have included the scientific research results of MCE customers；
• Our professional team tracks the latest pharmaceutical and life science research and provides you with the latest active compounds in the world；
• It has established long-term cooperation with the world's major pharmaceutical companies and well-known scientific research institutions。